Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The infection risks of JAK inhibition
Maryam Adas, Edward Alveyn, Emma Cook, et al.
Expert Review of Clinical Immunology (2021) Vol. 18, Iss. 3, pp. 253-261
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 47
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases (2025) Vol. 84, Iss. 2, pp. 188-200
Closed Access | Times Cited: 2
Advances in Synthetic Immunology for Targeted Treatment of Systemic Autoimmune Diseases: Opportunities, Challenges, and Future Directions
Galih Januar Adytia, Henry Sutanto, Laras Pratiwi, et al.
Immuno (2025) Vol. 5, Iss. 1, pp. 6-6
Open Access | Times Cited: 2
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber, Eugen Feist, Alan D. Irvine, et al.
Advances in Therapy (2022) Vol. 39, Iss. 11, pp. 4910-4960
Open Access | Times Cited: 39
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials
Sanghyuk Yoon, Kihun Kim, Kihyuk Shin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 52-61
Closed Access | Times Cited: 34
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Lise T. Jensen, Kathrine E. Attfield, Marc Feldmann, et al.
EBioMedicine (2023) Vol. 97, pp. 104840-104840
Open Access | Times Cited: 31
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 28
Infection risk with JAK inhibitors in dermatoses: a meta‐analysis
Patrick A. Ireland, Matthew J Verheyden, Nicholas Jansson, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 10
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Maddalena Napolitano, Maria Esposito, Maria Concetta Fargnoli, et al.
American Journal of Clinical Dermatology (2025)
Open Access | Times Cited: 1
A review of gut failure as a cause and consequence of critical illness
Danielle E. Soranno, Craig M. Coopersmith, Jessica F. Brinkworth, et al.
Critical Care (2025) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase
Sunny Park, M Kim, Sung Bin Park, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 394-394
Open Access | Times Cited: 1
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, et al.
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 32
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
Chrysoula G. Gialouri, Savvina Moustafa, Κonstantinos Thomas, et al.
Rheumatology International (2023) Vol. 43, Iss. 3, pp. 421-435
Open Access | Times Cited: 19
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Yuqin Song, Luis Malpica, Qingqing Cai, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 117-125
Closed Access | Times Cited: 18
Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1195-1203.e3
Closed Access | Times Cited: 8
Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review
Zhivana Boyadzhieva, Nikolas Ruffer, Gerd R Burmester, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 25
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Yijun Wu, Xu Sun, Kai Kang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council
Carter Haag, Andrew Alexis, Valéria Aoki, et al.
British Journal of Dermatology (2024)
Open Access | Times Cited: 5
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Gerd R Burmester, J. Stigler, Andrea Rubbert‐Roth, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 737-753
Open Access | Times Cited: 4
Deep insight into cytokine storm: from pathogenesis to treatment
Jiali Nie, Ling Zhou, Weiwei Tian, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children
Yan Du, Meng Liu, Peter A. Nigrović, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 151, Iss. 3, pp. 607-618
Open Access | Times Cited: 10
Septische muskuloskeletale Komplikationen unter immunmodulierender Therapie
Anna Kernder, C. Kneitz
Zeitschrift für Rheumatologie (2025)
Closed Access
Function of Interferon Lambda Receptor 1 Variants in Stem Cell-Derived Hepatocytes with Abrogated Endogenous IFNLR1
Laura A. Novotny, Christiana S. Kappler, Eric G. Meissner
Journal of Interferon & Cytokine Research (2025)
Closed Access
The small molecule ML233 is a direct inhibitor of tyrosinase function
Romain Menard, Aissette Baanannou, Caroline Halluin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
IL23p19 therapies for moderately-to-severely active ulcerative colitis
Newaz Shubidito Ahmed, Christopher Ma
Expert Opinion on Biological Therapy (2025)
Closed Access
Page 1 - Next Page

Scroll to top